drug
Efudex
Marketedupdated 3mo agoby Extrovis AG
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval132 co-mentions · 66 sources
- drugFAVLYXA73 co-mentions · 72 sources
- drugFLUOROURACIL72 co-mentions · 72 sources
- drugRNS-6012 co-mentions · 12 sources
- companyFresenius Kabi USA LLC12 co-mentions · 12 sources
- tagOncology5 co-mentions · 2 sources
- drugFOLFOX [leucovorin + fluorouracil + oxaliplatin]1 co-mentions · 1 sources
- drugOXALIPLATIN1 co-mentions · 1 sources
all catalysts(42)
approval · 40
Sep 30, 1998
approval
FLUOROURACIL — FDA approval
Efudex
→
Sep 30, 1998
approval
FLUOROURACIL — FDA approval
Efudex
→
Jul 6, 1999
approval
FLUOROURACIL — FDA approval
Efudex
→
Jul 6, 1999
approval
FLUOROURACIL — FDA approval
Efudex
→
Dec 5, 2002
approval
FLUOROURACIL — FDA approval
Efudex
→
Dec 5, 2002
approval
FLUOROURACIL — FDA approval
Efudex
→
Apr 26, 2007
approval
FLUOROURACIL — FDA approval
Efudex
→
Apr 26, 2007
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 17, 2016
approval
FLUOROURACIL — FDA approval
Efudex
→
Nov 14, 2016
approval
FLUOROURACIL — FDA approval
Efudex
→
Dec 27, 2016
approval
FLUOROURACIL — FDA approval
Efudex
→
Dec 27, 2016
approval
FLUOROURACIL — FDA approval
Efudex
→
Jan 6, 2017
approval
FLUOROURACIL — FDA approval
Efudex
→
Jan 6, 2017
approval
FLUOROURACIL — FDA approval
Efudex
→
May 11, 2017
approval
FLUOROURACIL — FDA approval
Efudex
→
Oct 27, 2017
approval
FLUOROURACIL — FDA approval
Efudex
→
Dec 26, 2017
approval
FLUOROURACIL — FDA approval
Efudex
→
Sep 14, 2022
approval
FLUOROURACIL — FDA approval
Efudex
→
Sep 14, 2022
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 3, 2023
approval
FLUOROURACIL — FDA approval
Efudex
→
Oct 18, 2023
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Mar 21, 2024
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 5, 2026
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 5, 2026
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 5, 2026
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 5, 2026
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 5, 2026
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 5, 2026
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 5, 2026
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 5, 2026
approval
FLUOROURACIL — FDA approval
Efudex
→
Feb 20, 2026
approval
FAVLYXA (FLUOROURACIL) — FDA approval
Efudex
→
phase 1 initiation · 1
Trials studying Efudex
- phase3A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
- phase1A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- phase3A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- phase3Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- phase1A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- phase3A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- phase1A Study of ASP3082 in Adults With Advanced Solid Tumors
- phase2A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer
News(1)
- Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic CancerDeirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.onclive · 3mo ago
Data sources
last refreshed 33m ago
Found something off?
comments(0)
5-min edit window · permanent after that